

CANADA—LET'S TAKE A BIGGER PIECE OF THE PIE

As Thanksgiving approaches we would like to extend our appreciation for your great contribution so far....and we challenge you to all help Canada take a bigger piece of the pie...we know you can!



CONGRATULATIONS TO THE FOLLOWING SITES FOR THEIR RANDOMIZATIONS THIS SUMMER!

Dr. Gilbert Gosselin
Molywan Vat
Montreal Heart Institute
3 Randomizations

Dr. Andrew Howarth
Michelle Seib, Rosa Sandonato,
Sandra Rivest
FOOTHILLS MEDICAL CENTRE
2 Randomizations

Dr. Paul Galiwango
Bev Bozek, Brenda Hart,
Maria Shier
SCARBOROUGH CARDIOLOGY
2 Randomizations

Dr. Shamir Mehta
Krystal Etherington
Hamilton General Hospital
1 Randomization

Dr. Ariel Diaz
Isabelle Roy
**CENTRE DE SANTÉ ET DE SERVICES
SOCIAUX DE TROIS-RIVIÈRES**
3 Randomizations

Dr. Kevin Bainey
Norma Hogg, Suzanne Welsh
UNIVERSITY OF ALBERTA HOSPITAL
3 Randomizations (1 CKD)

Dr. Asim Cheema
Mohammed Hussain
ST. MICHAEL'S HOSPITAL
1 Randomization

Dr. Graham Wong
Andrew Staovoytov
VANCOUVER GENERAL HOSPITAL
1 Randomization

Dr. James Cha
Judy Otis, Rebecca Otis
PRIVATE PRACTICE
3 Randomizations

Dr. Bill Kostuk
Dr. Rodrigo Bagur
Sandy Carr
UNIVERSITY HOSPITAL
2 Randomizations

Dr. Amar Uxa
Nadia Asif
UNIVERSITY HEALTH NETWORK
1 Randomization

Dr. Ledjalem Daba
Fran Farquharson
**Northwest GTA Cardiovascular and
Heart Rhythm
Program**
1 Randomization

HIGHLIGHT

Optimal Medical Therapy: What you can do to ensure medical therapy is optimized!

Optimal medical therapy (OMT) is the cornerstone of care for patients with stable ischemic heart disease (SIHD), including participants in the ISCHEMIA trial. Here are **key points to consider**:

- All ISCHEMIA participants should achieve an LDL < 1.81 mmol/L (70mg/dl) on the maximally tolerated dose of a high-intensity statin (atorvastatin (Lipitor) 80mg or rosuvastatin (Crestor) 40mg)
- We recommend long term (for the duration of the trial) dual anti-platelet therapy with aspirin and a P2Y12 inhibitor for all ISCHEMIA participants, regardless of treatment assigned, unless a history of bleeding is present
- Other important parameters of OMT include not smoking, a systolic blood pressure < 140 mm/Hg and the use of ACEi/ARB and beta-blockers, where indicated, as detailed in the OMT report
- Work with participants' Primary Care Physician or Primary Cardiologist if medications are managed by them; communication is key!
- Use the Morisky Medication Adherence survey routinely to assess participants' compliance with medication use

ANCILLARY TRIAL CORNER

Enrollment Tips



Please consider retrospective review (up to a year) of stress test databases, cath lab databases, dialysis lists, and transplant lists for potential participants.

- Participant eligibility criteria include:
 - Advanced CKD (eGFR <30 or on dialysis)
 - Abnormal stress test in the past 90 days (or in the past year with CCC approval)
 - Medically managed
- Patients that fulfill these criteria can be considered for enrollment

Establish effective screening of patients with angina or anginal equivalents (exertional shortness of breath, fatigue) by nephrologists and referral for stress test where appropriate

- Contact ISCHEMIA-CKD Lead Nephrologist Ron Wald (waldr@smh.ca) if you require assistance identifying a nephrologist
- Consider patients with abnormal stress test who are referred for pre-renal transplant clearance




The CIAO ancillary study is open for enrollment and new sites are welcome!

- CIAO will allow your site to continue to follow participants who were enrolled in the main trial via stress echocardiogram and were excluded from randomization due to non-obstructive CAD on the study CCTA
- There are **additional site payments for CIAO**
- Only **3 simple visits** are needed over one year with a repeat stress echocardiogram (paid for by the study) at the one year mark
- If your site performs stress echo and is interested in learning more about CIAO, please contact us at CIAO@nyumc.org

CANADIAN SITES HELP LEAD THE WAY IN DATA QUALITY

Congratulations! **3 sites in Canada** have been recognized for superior data quality during the past 6 months. In appreciation of their efforts, each site has received a Certificate of Excellence and an **Amazon.com gift eCertificate valued at \$25!**

 Dr. Gilbert Gosselin
Molywan Vat
MONTREAL HEART INSTITUTE

 Dr. Kevin Bainey
Norma Hogg,
Suzanne Welsh
UNIVERSITY OF ALBERTA
HOSPITAL

 Dr. Rodrigo Bagur
Sandy Carr
UNIVERSITY HOSPITAL

OTHER IMPORTANT UPDATES

ISCHEMIA-CKD Reference Cards and Posters are available upon request; please contact the CHRC for more information or to request a supply.

Country Leaders: Drs. Gilbert Gosselin, Vlad Dzavik & Shaun Goodman

ISCHEMIA-CKD Country Lead Cardiologists: Drs. Akshay Bagai & Kevin Bainey **ISCHEMIA-CKD Country Lead Nephrologist :** Dr. Ron Wald

CHRC Project Leader: Dr. Neamat Mowafy | Phone: 416.977.8010 | Email: mowafyn@CHRC.net

ISCHEMIA Clinical Coordinating Center Telephone: 1-212-263-4225 **Fax:** 1-646-754-9621 **Mailbox:** ischemia@nyumc.org

Website: www.ischemiatrial.org